Dr. Schiffer is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4100 John R St
Detroit, MI 48201Phone(800) 527-6266
Fax(313) 576-8767- Is this information wrong?
Education & Training
University of MarylandResidency, Internal Medicine, 1974 - 1975
NYU School of MedicineResidency, Internal Medicine, 1968 - 1972
NYU School of MedicineClass of 1968
Certifications & Licensure
MI State Medical License 1997 - 2022
MD State Medical License 1975 - 1997- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Fellow (FASCO) American Society of Clinical Oncologists, 2010
- Join now to see all
Clinical Trials
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia Start of enrollment: 2013 Apr 01Ravandi-Kashani, F.,Jones, J.A.,Call, T.G.,Schiffer, C.A.,DeAngelo, D.J.,Kreitman, R.J.
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 01Aribi, A.M.,Bseiso, A.W.,Conlin, A.K.,Keyzner, A.,Tabatabai, A.,DeZern, A.E.,Kew, A.K.,Advani, A.S.,Marchello, B.T.,Cooper, B.W.,Medeiros, B.C.,Yi, C.Y.,Schiffer, C.A.,Chay, C.H.,Reynolds, C.M.,Bixby, D.L...
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies. Start of enrollment: 2012 May 01Uberti, J.P.,Schiffer, C.A.,Ratanatharathorn, V.,Lum, L.G.,Ayash, L.J.
- Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies. Start of enrollment: 2012 May 01Ayash, L.J.,Uberti, J.P.,Schiffer, C.A.,Ratanatharathorn, V.,Lum, L.G.
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 01Tolentino, A.R.,List, A.F.,List, A.,Verma, A.K.,Sanyal, A.,Weise, A.M.,Artz, A.S.,Vemula, A.Y.,Kasimis, B.S.,Marchello, B.T.,Ansari, B.,Naqvi, B.H.,Cook, B.A.,Byrne, B.J.,Burnette, B.L.,Raphael, B.G.,Fall...
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2003 Jun 01Schiffer, C.A.
- S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2001 Aug 01Schiffer, C.A.
- Join now to see all
Publications & Presentations
PubMed
- Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji, Kathy L. McGraw, Jaroslaw P. Maciejewski, Jessica K. Altman, Puneet Cheema, David F. Claxton,...> ;Journal of Clinical Oncology. 2021 Jan 13
- The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.Erlene K. Seymour, Julie J. Ruterbusch, Aaron N. Winn, Julie George, Jennifer L. Beebe-Dimmer, Charles A. Schiffer> ;Cancer. 2021 Jan 1
- Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.Ehab Atallah, Charles A. Schiffer, Jerald P. Radich, Kevin P. Weinfurt, Mei-Jie Zhang, Javier Pinilla-Ibarz, Vamsi Kota, Richard A. Larson, Joseph O. Moore, Michael J....> ;JAMA Oncology. 2021 Jan 1
- Join now to see all
Journal Articles
- Promoting Apoptosis with Venetoclax — A Benefit for Older Patients with AMLCharles Schiffer, MD, New England Journal of Medicine
Abstracts/Posters
- Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...Charles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid LeukemiaCharles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral TherapeuticsCharles A. Schiffer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Other
- To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2012-02-14 - To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2013-03-20 - To What Extent Can Mathematical Modeling Inform the Design of Clinical Trials? The Example of Safe Dose Reduction of Tyrosine Kinase Inhibitors in Responding Patients ...Charles Schiffer, MD, Haematologica
https://www.doximity.com/articles/4681238f-f736-4d40-8426-f4cf919fa658
UpToDate, Wolters Kluwer Health - 2013-01-03 - Join now to see all
Authored Content
- Promoting Apoptosis with Venetoclax — A Benefit for Older Patients with AMLAugust 2020
Press Mentions
- Schiffer Spotlights Potential for TKI Discontinuation in Select Patients with CMLOctober 31, 2020 14:15
Combo Protocol Promising for Older AML PatientsAugust 14, 2020 10:51
Grant Support
- Transfusion Trial To Prevent Platelet AlloimmunizationNational Heart, Lung, And Blood Institute1994–1995
- Mechanisms Of Drug Resistance In Acute Myeloid LeukemiaNational Cancer Institute1990–1994
- Transfusion Trial To Prevent Platelet AllolimmunizationNational Heart, Lung, And Blood Institute1989–1993
- Mechanisms Of Platelet RefractorinessNational Heart, Lung, And Blood Institute1986–1988
Professional Memberships
- Fellow
Hospital Affiliations
DMC - Detroit Receiving HospitalDetroit, Michigan
DMC Harper University HospitalDetroit, Michigan
Karmanos Cancer CenterDetroit, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
